Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and PertuzumabHannah Dzimitrowicz, Michael Berger, Craig Vargo, et al.
BMC Cancer|December 21, 2018
A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanomaJennifer L McQuade, Jade Homsi, Carlos A Torres-Cabala, et al.
Physiological Measurement|March 23, 2018
Evaluation of surrogate measures of pulmonary function derived from electrical impedance tomography data in children with cystic fibrosisPeter A Muller, Jennifer L Mueller, Michelle Mellenthin, et al.
Sleep & Breathing = Schlaf & Atmung|September 3, 2024
Sleep disturbances based on patient reported outcomes in patients with breast cancerSaadia A Faiz, Ashley S Knox, Bryan Fellman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2025
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast CancerMohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava, et al.
Breast (Edinburgh, Scotland)|September 25, 2024
Financial toxicity in breast cancer patients receiving regional nodal irradiation: Variation by cancer subtypeGrace L Smith, Benjamin D Smith, Chi-Fang Wu, et al.
NPJ Breast Cancer|June 25, 2019
SET<sub>ER/PR</sub>: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancerBruno V Sinn, Chunxiao Fu, Rosanna Lau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian CancerShannon N Westin, Marilyne Labrie, Jennifer K Litton, et al.
NPJ Breast Cancer|May 13, 2021
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036Steven P Angus, Timothy J Stuhlmiller, Gaurav Mehta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 TrialA Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Pageof 3